Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
compound 15b
it is selectively and irreversibly converted to its active phosphoramidate-based
EMT inhibitor-1 induces GSK3-β–mediated degradation of the Hippo transducer TAZ
) lower MAP over 24 hours in normotensive wild-type mice but not in KCa3
3-oxazolidin-4-yl]-7-methoxy-6-methyl-8-(prop-2-en-1-yloxy)-1
(-)-Cevimeline hydrochloride hemihydrate Catalog No.:M34745-C compound 15b( ) Cevimeline hydrochloride hemihydrate (( ) SNI 2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI 2011 was also evaluated with rat and dog liver
US$ 12.95
US$ 15.95
US$ 16.95
US$ 28.00